



Agenda

1/9

Day 1 / September 3, 2025

Public Health & AI Innovations in Oncology

08:00 – 09:00 Registration & Coffee

09:00 – 09:10 Welcome and Introduction to the conference

Beata Jagielska, MSCI Director

09:10 – 11:30

SESSION 1

Innovative Public Health Policies

SESSION 1

Duration: 2,3 h

Developing and implementing new policies
to enhance cancer prevention, and screening accessibility.

SESSION CHAIRS: Marta Mańczuk (Poland) and Marc Parascandola (USA)

09:10 – 09:15	Welcome and introduction to the session	Marta Mańczuk Marc Parascandola
09:15 – 09:30	Targeted Nicotine Prevention Strategies for Cancer Control: Qualitative Insights from Poland	Julia Nowicka
09:30 – 10:00	Building Transatlantic Collaboration “Innovative Public Health Policies – Pathways for Polish–US Cooperation” / <i>Joint Presentation</i>	Mark Parascandola Marta Mańczuk
10:00 – 10:30	National Cancer Mission Hubs – complementary approach towards public health policies	Iwona Ługowska
10:30 – 11:20	Scaling Innovative Public Health Interventions: From Evidence to Impact <i>Panel Discussion and Audience Q&A</i>	Mark Parascandola, Marta Mańczuk, Łukasz Balwicki, Iwona Ługowska <i>Moderator: Monika Dzieńyńska-Dyk</i>
11:20 – 11:30	Closing remarks	

11:30 – 12:30 Lunch

12:30 – 15:00 SESSION 2 / on the next page →

Notes



Agenda

2/9

Day 1 / September 3, 2025

Public Health & AI Innovations in Oncology

12:30 – 15:00

SESSION 2

Global Health Initiatives

SESSION 2

Duration: 2,5 h

Addressing cancer disparities worldwide, improving healthcare access in underserved population by fostering global collaborations.

SESSION CHAIRS: Iwona Ługowska (Poland) and Leszek Kotula (USA)

12:30 – 12:40

Welcome and Introduction

Iwona Ługowska
Leszek Kotula

12:40 – 13:00

Mission Cancer and Eu4Health: extensive synergy towards understanding cancer, prevention and early detection, diagnosis and treatment, and improving quality of life in Europe

Iwona Ługowska

13:00 – 13:20

Bridging Cancer Care and Research Gaps in Croatia: The CORN-CCI4EU Deep Dive

Iva Kirac

13:20 – 13:40

Curie4Curie: A Model of International Scientific Collaboration Between Institut Curie and the Maria Skłodowska-Curie National Research Institute of Oncology

Izabela Agnieszczak

13:40 – 13:50

Q&A

13:50 – 14:10

Opportunities for Global Cancer Research and Collaboration at the NCI

Marc Parascandola

14:10 – 14:30

Initiating the Global Network for Cancer Prevention and Early Treatment

Leszek Kotula

14:30 – 14:50

Comparing Student-Led Oncology Initiatives in North America and Europe: A Global Perspective

Paulina Kalman

14:50 – 15:00

Q&A and closing remarks

15:00 – 15:30 Coffee break

15:30 – 17:30 SESSION 3 / on the next page →



Agenda

3/9

Day 1 / September 3, 2025

Public Health & AI Innovations in Oncology

15:30 – 17:30

SESSION 3

Data and AI in oncology

SESSION 3

Duration: 2 h

Data and AI oncology

SESSION CHAIRS: Magdalena Rosińska (Poland)

15:30 – 15:35	Welcome and Introduction	Magdalena Rosińska
15:35 – 15:50	From Data to Discovery: How Regional Digital Medicine Centres Are Shaping the Future of Precision Medicine in Poland	Zuzanna Nowak-Życzyńska
15:50 – 16:05	Transforming Clinical Trial Data Collection: The EFTISARC-NEO Case	Jan Poleszczuk
16:05 – 16:20	Comparison of lightweight large language models for data retrieval in bone sarcomas	Paweł Teterycz
16:20 – 16:35	Deep learning-guided design and experimental validation of selective antibodies for oncological applications	Sandra Skorupska
16:35 – 16:50	Harnessing Machine Learning for Precision Prognostication in Pancreatic Ductal Adenocarcinoma	Bogdan Ungureanu
16:50 – 17:05	AI4AR: The Role of Reporting, Education, and Artificial Intelligence in the era of Value-Based Radiology	Rafał Józwiak
17:05 – 17:30	Q&A and closing remarks	

Coctail

08:45 – 11:30 [DAY 2 – SESSION 1](#) / on the next page →

Notes

.....

.....

.....

.....



Day 2 / September 4, 2025

Breakthroughs in Oncology & Oncology Collaboration

08:45 – 11:30

SESSION 1

Immunotherapy

SESSION 1

Duration: 2,75 h

Advancements in immunotherapy and clinical trials.

SESSION CHAIRS: Piotr Rutkowski (Poland) and Tom Gajewski (USA)

08:45 – 08:50	Welcome and Introduction	Piotr Rutkowski, Tom Gajewski
08:50 – 09:05	Lithuania's current reimbursement landscape for innovative cancer therapies	Vincas Urbonas
09:05 – 09:15	Chemokine Modulation (CKM): Sensitizing the Tumor Microenvironment to PD-1 Blockade with a TLR-3 ligand and Type-I IFN Combinatorial Approach	Kathleen Kokolus
09:15 – 09:25	Chemokine-Modulating Regimen (CKM) Rintatolimod plus IFN** in Patient with Solid Tumors Patients Reprograms "Cold" Tumors for Enhanced CTL Influx	Pawel Kaliński
09:25 – 09:35	Cardiological predictors of balstilimab efficacy in the treatment of non-melanoma skin cancers: Results from the AGENONMELA phase II trial	Mateusz Iwański
09:35 – 09:45	Anti-GD2 Immunotherapy in Ewing Sarcoma: Preliminary Data from the Butterfly Project	Anna Zelwiańska
09:45 – 10:00	A first-in-human trial of intrathecal cDC1 therapy for breast cancer leptomeningeal disease induces adaptive immunity with transcriptomic evidence of immune awakening in the CSF	Peter Forsyth
10:00 – 10:20	Q&A	
10:20 – 10:30	Dendritic Cells in Cancer Immunotherapy: Vaccines, Live Adjuvants and T Cell Therapies with DC-sensitized T Cells	Paweł Kaliński
10:30 – 10:40	The Immune Microenvironment in Myelodysplastic syndromes	Michael Nemeth
10:40 – 10:50	Immunomodulatory and clinical impact of chronic stress-related beta-adrenergic signaling	Benjamin Switzer
10:50 – 11:00	Intratumoral delivery of conventional dendritic cells pulsed with MHC class II peptides and alpha-galactosyl-ceramide leads to eradication of disseminated cancer cells	Brian Czarniecki
11:00 – 11:10	From Propolis to STAT3 Inhibitors to Clinical Studies	Waldemar Priebe
11:10 – 11:30	Q&A and closing remarks	

11:30 – 12:30 Lunch

12:30 – 15:00 DAY 2 – SESSION 2 / on the next page →



Agenda

5/9

Day 2 / September 4, 2025

Breakthroughs in Oncology & Oncology Collaboration

12:30 – 15:00

SESSION 2

Precision Medicine

SESSION 2

Duration: 2,5 h

Advancements in targeted cancer therapies.

SESSION CHAIRS: Iwona Ługowska (Poland) and Mikhail Berezin (USA)

12:30 – 12:35	Welcome and Introduction	Iwona Ługowska, Mikhail Berezin
12:35 – 12:50	Mechanism of Chemotherapy -induced Peripheral neuropathy based on RNA sequencing data and bioinformatics	Mikhail Berezin
12:50 – 13:05	Chronodiagnosis: Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma	Tatiana Simon
13:05 – 13:20	Genetic signature of soft tissue sarcoma	Klaudia Bobak
13:20 – 13:35	Transcriptome and TCR repertoire in human telomerase reverse transcriptase peptide vaccine treated metastatic prostate cancer patients	Alfonso Urbanucci
13:35 – 13:45	Q&A	
13:45 – 14:00	Integrative MicroRNA Profiling in Chondrosarcoma: Toward Biomarker Discovery and Prognostic Signature Development	Mritunjoy Dey
14:00 – 14:15	Matching Clinical Trials with Molecular Profiles: A Searchable Database Developed by Center of Excellence for Precision Oncology	Paweł Michalak
14:15 – 14:30	Molecular Tumor Boards – Integration, Diversity of Practice, and European Collaboration: Experience from the Maria Skłodowska-Curie Institute	Izabela Agnieszczak
14:30 – 14:45	Ampligen As a Novel Immunotherapy for Endometriosis	Thomas Equels William Mitchell
14:45 – 15:00	Q&A and closing remarks	

15:00 – 15:30 Coffee break

15:30 – 17:30 DAY 2 – SESSION 3 / on the next page →



Agenda

6/9

Day 2 / September 4, 2025

Breakthroughs in Oncology & Oncology Collaboration

15:30 – 17:30

SESSION 3

Academia-HealthCare-Biotech Collaboration

SESSION 3

Duration: 2 h

Overcoming challenges in research partnerships: Bridging Science, Policy and Industry.

SESSION CHAIRS: Wojciech Fendler (Poland), Paweł Kaliński (USA), Piotr Wiślak (Poland)

15:30 – 15:35

Welcome and Introduction

Wojciech Fendler
Paweł Kaliński
Piotr Wiślak

15:35 – 15:55

Identifying new cancer immunotherapy strategies
through reverse translation from clinical samples

Tom Gajewski

15:55 – 16:25

Sponsorship session: Ampligen Breakthroughs
in Treating Late-Stage Pancreatic Cancer

Thomas Equels

16:25 – 17:00

Overcoming challenges in research partnerships:
Bridging Science, Policy and Industry –
Pentahelix approach

Wojciech Fendler (policymakers)
Paweł Kaliński (research)
Iwona Ługowska (healthcare)
Maja Hugod (industry)
Lidia Dyndor (PAG)
Moderator: Piotr Wiślak

17:00 – 17:30

Poster session

09:00 – 11:30 [DAY 3 – SESSION 1](#) / on the next page →

Notes



Agenda

7/9

Day 3 / September 5, 2025

Emerging Innovations in Cancer (Basic) Research

09:00 – 11:30

SESSION 1

Functional Precision Oncology

SESSION 1

Duration: 2,5 h

Keynote addresses and panel discussions
on future directions in oncology.

SESSION CHAIRS: Michał Mikula (Poland) and Alana Welm (USA)

09:00 – 09:05	Welcome and Introduction	Michał Mikula, Alana Welm
09:05 – 09:35	Modeling metastatic breast cancer to advance therapeutic strategies	Alana Welm
09:35 – 09:55	Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	Andrzej Mazan
09:55 – 10:15	Driver oncogene cooperation and competition in cancer	Dawid Walerych
10:15 – 10:35	Xenosarc: A Panel of Patient-Derived Xenograft Models of Sarcoma for Preclinical Drug Evaluation	Agnieszka Wozniak
10:35 – 10:45	AD-O51.4 – harnessing the power of natural apoptosis	Maria Mazur
10:45 – 10:55	Development of high-content screening (HCS)-based methodology for the purpose of functional precision oncology	Jaroslav Cendrowski
10:55 – 11:05	Q&A	
11:05 – 11:15	Modelling immune-excluded tumors in murine breast cancer models using 3D spheroid injections	Agata Mlynska
11:15 – 11:25	Organotropism Guided Design and Development of Novel Anticancer Agents	Waldemar Priebe
11:25 – 11:30	Closing remarks	

11:30 – 12:30 Lunch

12:30 – 15:00 DAY 3 – SESSION 2 / on the next page →



Agenda

8/9

Day 3 / September 5, 2025

Emerging Innovations in Cancer (Basic) Research

12:30 – 15:00

SESSION 2

Tumor Immuno MicroEnvironment

SESSION 2

Duration: 2,5 h

SESSION CHAIRS: Elżbieta Sarnowska (Poland) and Marcin Kortylewski (USA)

12:30 – 12:35	Welcome and Introduction	Elżbieta Sarnowska (Poland), Marcin Kortylewski (USA)
12:35 – 12:55	The pentose phosphate pathway of glucose metabolism integrates environmental and genetic mechanisms of carcinogenesis	Andras Perl
12:55 – 13:15	Androgen controls ABI1-mediated T cell function-sex driven incidence of diffuse alveolar hemorrhage in the pristane model of Systemic Lupus Erythematosus.	Leszek Kotula
13:15 – 13:35	Anti-cancer immunogenic potential of photocontrolled analogues of natural cytotoxic peptides	Natalia Khranovska
13:35 – 13:55	Thiopurine-Based Oligonucleotide for Targeted Telomere Damage in Leukemia and Lymphoma Cell in Vivo	Marcin Kortylewski
13:55 – 14:05	Q&A	
14:05 – 14:15	Soluble PD-1/PD-L1 as Biomarkers in Prostate Cancer: Immune Landscape and Clinical Significance	Margarite Zvirble
14:15 – 14:25	Cancer cell clonal evolution in vitro alters ovarian cancer cell line model resulting in drug response changes	Egle Zymantaite
14:25 – 14:35	Microbiota and Antitumor Immunity: Mechanisms at the Cellular and Molecular Level	Yuliia Shvets
14:35 – 14:45	A Modular Closed Cell Culture System to Improve Translatability and Reproducibility for Cancer Cell Therapies	Alicia D. Henn
14:45 – 14:55	Advanced mouse models: an unavoidable bridge between in vitro and clinical trials in oncology	Magdalena Cybulska-Lubak
14:55 – 15:00	Closing remarks	
15:00 – 15:30	<u>Coffee break</u>	



5th Annual
Marie Skłodowska-Curie
Symposium on Cancer
Research and Care

September 3-5, 2025
Warsaw, Poland
<https://mscsymposium.pl>

Agenda

9/9

Partners

